11,316 results match your criteria Adrenal Carcinoma

A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment.

Clin J Gastroenterol 2022 May 18. Epub 2022 May 18.

Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, 36 Takamatsu-cho, Takasaki, Gunma, 370-0829, Japan.

We herein report a case of huge hepatocellular carcinoma (HCC) with adrenal metastasis and vascular invasion successfully treated by conversion hepatectomy after atezolizumab-bevacizumab treatment. A 77-year-old male patient with chest pain was admitted. He had a history of HCC treatment; however, the patient stopped receiving follow-up treatment based on his own decision. Read More

View Article and Full-Text PDF

FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma.

Endocrine 2022 May 18. Epub 2022 May 18.

Division of Endocrinology, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany.

FGF/FGFR signaling regulates embryogenesis, angiogenesis, tissue homeostasis and wound repair by modulating proliferation, differentiation, survival, migration and metabolism of target cells. Understandably, compelling evidence for deregulated FGF signaling in the development and progression of different types of tumors continue to emerge and FGFR inhibitors arise as potential targeted therapeutic agents, particularly in tumors harboring aberrant FGFR signaling. There is first evidence of a dual role of the FGF/FGFR system in both organogenesis and tumorigenesis, of which this review aims to provide an overview. Read More

View Article and Full-Text PDF

S-GRAS score performs better than a model from SEER for patients with adrenocortical carcinoma.

Endocr Connect 2022 May 1. Epub 2022 May 1.

D Xu, Department of Urology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China.

Purpose: To externally validate the performance of the S-GRAS score and a model from the SEER database in a Chinese cohort of patients with adrenocortical carcinoma (ACC).

Methods: We first developed a model using data from the SEER database, after which we retrospectively reviewed 51 ACC patients hospitalized between 2013 and 2018, and we finally validated the model and S-GRAS score in this Chinese cohort.

Results: Patient age at diagnosis, tumor size, TNM stage, and radiotherapy were used to construct the model, and the Harrell's C-index of the model in the training set was 0. Read More

View Article and Full-Text PDF

Iliac vein deep vein thrombosis as an atypical presentation of an adrenocortical carcinoma.

BMJ Case Rep 2022 May 17;15(5). Epub 2022 May 17.

Department of Histopathology, Royal Oldham Hospital, Oldham, UK.

Adrenocortical carcinoma (ACC) is a rare form of cancer with an annual incidence of two per million. The risk of venous thromboembolism increases sevenfold in patients with cancer. This case report describes an iliac vein deep vein thrombosis (DVT) as an atypical presentation of an ACC and highlights the value of further imaging investigation in patients with unprovoked DVTs. Read More

View Article and Full-Text PDF

The value of as prognostic and immunological biomarker in pan-cancer.

Ann Transl Med 2022 Apr;10(8):466

Department of Thoracic Surgery, Tangdu Hospital, The Air Force Military Medical University, Xi'an, China.

Background: Finding new immune-related biomarkers is one of the promising research directions for tumor immunotherapy. The gene could stimulate the WNT pathway and regulate the progression of various tumors. Recent studies have partially revealed the relationship between and tumor immunity, but the correlation and underlying mechanisms in pan-cancer remain obscure. Read More

View Article and Full-Text PDF

Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma.

BMC Endocr Disord 2022 May 14;22(1):130. Epub 2022 May 14.

Department of Rheumatology and Immunology, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157, West Five Road, Xi'an, 710000, Shaanxi Province, China.

Background: Adrenocortical carcinoma (ACC) is a highly malignant urologic cancer and tends to metastasize. Although immune checkpoint inhibitors (ICIs) bring a glimmer of light to conquer ACC, only a fraction of patients have benefit from ICIs treatment. It is well known that tumor mutational burden (TMB) is closely associated with the efficacy and response rate of immunotherapy. Read More

View Article and Full-Text PDF

Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen.

Endocrine 2022 May 14. Epub 2022 May 14.

Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy.

Purpose: The management of patients with advanced/metastatic adrenocortical carcinoma (ACC) is challenging, EDP-M (etoposide, doxorubicin, cisplatin combined with mitotane) is the standard regimen. However, it is quite toxic, so an adequate supportive therapy is crucial to reduce as much as possible the side effects and maintain the dose intensity of cytotoxic agents.

Methods: We describe the main side effects of the EDP-M scheme and the best way to manage them based on the experience of the Medical Oncology Unit of the Spedali Civili of Brescia. Read More

View Article and Full-Text PDF

Screening for Prognostic Biomarkers in Metastatic Adrenocortical Carcinoma by Tissue Micro Arrays Analysis Identifies P53 as an Independent Prognostic Marker of Overall Survival.

Cancers (Basel) 2022 Apr 29;14(9). Epub 2022 Apr 29.

Department of Endocrine Oncology, Gustave Roussy, 94805 Villejuif, France.

Advanced adrenocortical carcinoma (ACC) has poor but heterogeneous prognosis. Apart from Ki67 index, no prognostic or predictive biomarker has been validated in advanced ACC, so far. We aimed at analyzing expression of a large panel of proteins involved in known altered pathways in ACC (cell cycle, Wnt/ß-catenin, methylation) to identify and prioritize potential prognostic or predictive parameters metastatic ACC population. Read More

View Article and Full-Text PDF

A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma.

Cells 2022 Apr 24;11(9). Epub 2022 Apr 24.

Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), 8091 Zürich, Switzerland.

Adrenocortical carcinoma is a heterogeneous and aggressive cancer that originates from steroidogenic cells within the adrenal cortex. In this study, we have assessed for the preclinical gold standard NCI-H295 in direct comparison with the more recently established MUC-1 and a here newly reported ACC cell line (TVBF-7) the mutational status of important driver genes (TP53, MEN1, PRKAR1A, CTNNB1, APC, ZNRF-3, IGF-2, EGFR, RB1, BRCA1, BRCA2, RET, GNAS and PTEN), Wnt-signaling specificities (CTNNB1 mutation vs. APC mutation vs. Read More

View Article and Full-Text PDF

Liquid biopsy for the assessment of adrenal cancer heterogeneity: where do we stand?

Endocrine 2022 May 13. Epub 2022 May 13.

Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, H-1083, Budapest, Hungary.

Almost 10 years have passed since the first attempts of liquid biopsy aimed at the characterisation of tumor cells present in the bloodstream from a regular sample of peripheral blood were performed. Liquid biopsy has been used to characterise tumor heterogeneity in various types of solid tumors including adrenocortical carcinoma. The development of molecular biology, genetics, and methodological advances such as digital PCR and next-generation sequencing allowed us to use besides circulating tumor cells a variety of circulating cell-free nucleic acids, DNAs, RNAs and microRNAs secreted by tumors into blood and other body fluids as specific molecular markers. Read More

View Article and Full-Text PDF

Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies.

Endocr Rev 2022 May 13. Epub 2022 May 13.

Department of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, MI, USA.

The adrenal glands are paired endocrine organs that produce steroid hormones and catecholamines required for life. Adrenocortical carcinoma (ACC) is a rare and often fatal cancer of the peripheral domain of the gland, the adrenal cortex. Recent research in adrenal development, homeostasis, and disease have refined our understanding of the cellular and molecular programs controlling cortical growth and renewal, uncovering crucial clues into how physiologic programs are hijacked in early and late stages of malignant neoplasia. Read More

View Article and Full-Text PDF

Safety of Minimally Invasive Surgical Techniques in Large Adrenal Lesions: A Single-Centre Study.

J Coll Physicians Surg Pak 2022 May;32(5):565-569

Department of Urology, Hacettepe University School of Medicine, Ankara, Turkey.

Objective: To compare perioperative outcomes of minimally invasive surgery for ≥5 cm and <5 cm adrenal lesions.

Study Design: Retrospective cohort study.

Place And Duration Of Study: Hacettepe University School of Medicine, Ankara, Turkey, between October 2007 and September 2019. Read More

View Article and Full-Text PDF

Simultaneous Detection of 2 Types of Malignancies in a Pediatric Patient on FDG PET/CT Led to Diagnosis of Li-Fraumeni Syndrome.

Clin Nucl Med 2022 May 11. Epub 2022 May 11.

From the Department of Nuclear Medicine, Beijing Friendship Hospital of Capital Medical University, Beijing, China.

Abstract: A 17-month-old girl underwent FDG PET/CT to evaluate a right adrenal lesion, which showed abnormal 18F-FDG avidity. In addition, an unexpected lesion with mild 18F-FDG uptake was noted in the right anterior thoracic wall. Pathology demonstrated adrenocortical carcinoma in the right adrenal and rhabdosarcoma in both the left forearm and right anterior thoracic wall. Read More

View Article and Full-Text PDF

ASO Author Reflections: The Impact of Oncocytic Histology on Survival in Adrenocortical Carcinoma.

Ann Surg Oncol 2022 May 10. Epub 2022 May 10.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article and Full-Text PDF

Inter-individual comparison of diagnostic accuracy of adrenal washout CT compared to chemical shift MRI plus the T2-weighted (T2W) adrenal MRI calculator in indeterminate adrenal masses: a retrospective non-inferiority study.

Abdom Radiol (NY) 2022 May 10. Epub 2022 May 10.

Department of Medical Imaging, The Ottawa Hospital, University of Ottawa, 1053 Carling Avenue, C1 Radiology, Ottawa, ON, K1Y 4E9, Canada.

Objective: To compare diagnostic accuracy of washout (WO)-CT to chemical shift (CS)-MRI + T2W adrenal MRI Calculator (T2W-Calculator) to diagnose adrenal adenoma in indeterminate adrenal masses.

Methods: This retrospective, cross-sectional, non-inferiority study evaluated 40 consecutive indeterminate adrenal masses; each with WO-CT and MRI. Two blinded radiologists independently evaluated in mixed order: pre-contrast attenuation (Hounsfield Units, HU) and absolute WO ([Peak. Read More

View Article and Full-Text PDF

Metastatic prostate carcinoma presenting as a gluteal soft tissue mass.

Ther Adv Urol 2022 Jan-Dec;14:17562872221096384. Epub 2022 May 4.

JDW Pathology Inc., Cape Town, South Africa.

Metastatic lesions from prostate adenocarcinoma to the bone and lymph nodes and less frequently to the lungs, pleura, liver and adrenal glands are well documented. The presence of soft tissue metastases from a prostate adenocarcinoma is extremely rare. We report a case of a 56-year-old male who presented with a 2-year history of a painless buttock mass. Read More

View Article and Full-Text PDF

HNRNPA2B1 Demonstrates Diagnostic and Prognostic Values Based on Pan-Cancer Analyses.

Comput Math Methods Med 2022 27;2022:9867660. Epub 2022 Apr 27.

Department of Thoracic Surgery, Xiamen University Institute of Chest and Lung Disease, Xiang'an Hospital of Xiamen University, China.

Some studies have suggested heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1) to be a promoter in cancer development. Nonetheless, no detailed pan-cancer investigation has been reported. Thus, this study explored the possible oncogenic role of HNRNPA2B1, such as its expression levels, gene alteration, protein-protein interaction network, immune infiltration, and prognostic value in different cancer types using The Cancer Genome Atlas web platform. Read More

View Article and Full-Text PDF

Impact of RSUME Actions on Biomolecular Modifications in Physio-Pathological Processes.

Front Endocrinol (Lausanne) 2022 21;13:864780. Epub 2022 Apr 21.

Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) - Partner Institute of the Max Planck Society, Buenos Aires, Argentina.

The small RWD domain-containing protein called RSUME or RWDD3 was cloned from pituitary tumor cells with increasing tumorigenic and angiogenic proficiency. RSUME expression is induced under hypoxia or heat shock and is upregulated, at several pathophysiological stages, in tissues like pituitary, kidney, heart, pancreas, or adrenal gland. To date, several factors with essential roles in endocrine-related cancer appear to be modulated by RWDD3. Read More

View Article and Full-Text PDF

Expression of p11 and heteromeric TASK channels in mouse adrenal cortical cells and H295R cells.

Acta Histochem 2022 May 5;124(5):151898. Epub 2022 May 5.

Department of Cell and Systems Physiology, University of Occupational and Environmental Health School of Medicine, Kitakyushu 807-8555, Japan. Electronic address:

TWIK-related acid-sensitive K (TASK) channels are thought to contribute to the resting membrane potential in adrenal cortical (AC) cells. However, the molecular identity of TASK channels in AC cells have not yet been elucidated. Thus, immunocytochemical and molecular biological approaches were employed to investigate the expression and intracellular distribution of TASK1 and TASK3 in mouse AC cells and H295R cells derived from human adrenocortical carcinoma. Read More

View Article and Full-Text PDF

Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma.

Endocr Relat Cancer 2022 Apr 1. Epub 2022 Apr 1.

Y Bi, Department of Endocrinology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.

Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis and challenging management. The present study aimed to investigate expression of programmed death ligand-1 (PD-L1) and V-domain Ig-containing suppressor of T cell activation (VISTA) in ACC and their associations with clinicopathological features and survival outcomes. Immunohistochemistry was performed on formalin-fixed paraffin-embedded specimens from 54 ACC patients. Read More

View Article and Full-Text PDF

Primary renal sarcoma with SS18::POU5F1 gene fusion.

Genes Chromosomes Cancer 2022 May 6. Epub 2022 May 6.

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, United States.

We report the first case of a primary renal undifferentiated sarcoma harboring an SS18::POU5F1 gene fusion. The patient was a 38 year-old male diagnosed with a 5 cm renal tumor which invaded the adrenal gland and extended into the renal vein. Microscopically, the neoplasm had a predominantly undifferentiated round cell morphology, with areas of rhabdoid and spindle cell growth. Read More

View Article and Full-Text PDF

Epstein-Barr virus-related diffuse large B-cell lymphoma type methotrexate-associated lymphoproliferative disorders presenting in the adrenal gland.

IJU Case Rep 2022 May 8;5(3):172-174. Epub 2022 Mar 8.

Department of Urology Hyogo Prefectural Amagasaki General Medical Center Amagasaki-shi Hyogo Japan.

Introduction: Methotrexate-associated lymphoproliferative disorders appear during treatment with methotrexate as an immunosuppressive drug. However, the mechanism and frequency are still unknown, and the treatment is undefined.

Case Presentation: A 76-year-old woman was admitted to the hospital with back pain, and magnetic resonance imaging showed a tumor in the right adrenal region. Read More

View Article and Full-Text PDF

Adrenal cortical carcinoma: a natural progress.

Korean J Intern Med 2022 May 4. Epub 2022 May 4.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

View Article and Full-Text PDF

Histopathological Criteria for Paediatric Adrenal Cortical Carcinoma.

Horm Res Paediatr 2022 May 4. Epub 2022 May 4.

Introduction: Adrenocortical carcinoma (ACC) is diagnosed in paediatric patients at 5 months after symptom onset on average, and 38% die during the first 2.5 years of follow-up. This study aimed to compare the accuracy of Weiss, Van Slooten, and Wieneke histopathological ACC classifications for predicting follow-up prognosis in a paediatric population. Read More

View Article and Full-Text PDF

Diagnostic dilemmas: a multi-institutional retrospective analysis of adrenal incidentaloma pathology based on radiographic size.

BMC Urol 2022 Apr 30;22(1):73. Epub 2022 Apr 30.

Department of Urology, West Virginia University, 1 Medical Center Drive, Morgantown, WV, 26505, USA.

Introduction/background: Adrenal incidentalomas (AIs) are masses > 1 cm found incidentally during radiographic imaging. They are present in up to 4.4% of patients undergoing CT scan, and incidence is increasing with usage and sensitivity of cross-sectional imaging. Read More

View Article and Full-Text PDF

Ferroptosis-based molecular prognostic model for adrenocortical carcinoma based on least absolute shrinkage and selection operator regression.

J Clin Lab Anal 2022 May 2:e24465. Epub 2022 May 2.

Department of Endocrinology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Background: This study aimed to find ferroptosis-related genes linked to clinical outcomes of adrenocortical carcinoma (ACC) and assess the prognostic value of the model.

Methods: We downloaded the mRNA sequencing data and patient clinical data of 78 ACC patients from the TCGA data portal. Candidate ferroptosis-related genes were screened by univariate regression analysis, machine-learning least absolute shrinkage, and selection operator (LASSO). Read More

View Article and Full-Text PDF

Differences in Clinicopathologic Behavior of Oncocytic Adrenocortical Neoplasms and Conventional Adrenocortical Carcinomas.

Ann Surg Oncol 2022 Apr 30. Epub 2022 Apr 30.

Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Oncocytic adrenocortical neoplasms (OANs) are rare endocrine tumors that present as a spectrum from benign to malignant. The outcomes after surgical resection of the oncocytic variant of adrenocortical carcinoma remain poorly understood. We sought to characterize the clinicopathologic features of OAN and compare oncocytic adrenocortical carcinoma (OAC) with conventional adrenocortical carcinoma (ACC). Read More

View Article and Full-Text PDF

Cutaneous Metastases and Long-Term Survival of a Patient With Clear Cell Renal Carcinoma.

Cureus 2022 Mar 29;14(3):e23598. Epub 2022 Mar 29.

Oncology, Hospital Pedro Hispano, Matosinhos, PRT.

The treatment landscape of metastatic renal cell carcinoma (mRCC) has changed in the last decade with improvements in overall survival. Overall survival ranges from 57 months in good-to-intermediate prognosis patients to 19 months in poor prognosis patients. The most frequent sites of metastasis are the lungs, bone, distant lymph nodes, liver, adrenal, and brain. Read More

View Article and Full-Text PDF